Chronic or active hepatitis B or C, requiring antiviral therapy
Patients with history of hepatitis B and hepatitis C will be eligible but patients with hepatitis B must be started on antiviral therapy prior to beginning study therapy
Patients with hepatitis B infection must be on appropriate antiviral therapy
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigators opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or known active infection including chronic active hepatitis B, hepatitis C and human immunodeficiency virus (HIV); screening for chronic conditions is not required; patients with chronic hepatitis B virus (HBV) with negative HBV viral load on appropriate antiviral therapy will be permitted, if able to continue appropriate antiviral therapy throughout treatment period
Chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Patients with hepatitis B infection must be on appropriate antiviral therapy
Chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Chronic or active hepatitis B or C if not controlled by antiviral therapy
Patients with active Hepatitis B infection (HBsAg positive) that are not receiving antiviral treatment are excluded
Per PI discretion, active infection that is not well controlled by antibacterial or antiviral therapy.
Patients known to be have active hepatitis B or C; (hepatitis B positive patients are allowed if they are on appropriate antiviral agents such as lamivudine)
Chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
Treatment with appropriate antiviral therapy for patients with active HBV infection is required
Active infection not well controlled by antibacterial or antiviral therapy.
Antiviral therapy per local standard of care if active hepatitis B (HBV) infection.
Known significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for hepatitis B surface antigen or hepatitis C antibodies are allowed provided they do not have active disease requiring antiviral therapy)
Known to have active hepatitis C infection (positive by polymerase chain reaction) or on antiviral therapy for hepatitis C within  months prior to the first doses of brentuximab vedotin and lenalidomide
Active hepatitis B, unless patient has been on antiviral agents for at least  months (baseline testing not required)
Have achieved a sustained virologic response for  weeks after cessation of hepatitis C antiviral treatment (in HIV-positive subjects with hepatitis C)
Has known active Hepatitis B unless subject has been on antiviral agents for at least  months (baseline testing not required)
Patients with active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
Presence of known hepatitis B or hepatitis C infection, regardless of control on antiviral therapy
Subjects with known active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy.
Have either active or chronic hepatitis B or C requiring treatment with antiviral therapy.
Known HIV-positive individuals on combination antiretroviral therapy, patients with known active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
Known to be positive for hepatitis B. Known to have active hepatitis C infection or on antiviral therapy for hepatitis C within the last  months.
Chronic or active hepatitis B or C, requiring antiviral therapy
Known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last  months)
Active Hepatitis B infection in the absence of adequate antiviral therapy
Chronic or active hepatitis B or C, requiring antiviral therapy
Known significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for hepatitis B surface antigen or hepatitis C antibodies are allowed provided they do not have active disease requiring antiviral therapy)
Patients must be on antiviral therapy per the local standard of care if active or occult hepatitis B (hepatitis B virus [HBV]) infection; patients with active hepatitis C (hepatitis C virus [HCV]) may not be antiviral therapy